Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 5/20 | 0.57 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.52 |
| ▸ | TTBK2 | Q6IQ55 | 1/20 | 0.52 |
| ▸ | BRAF | P15056 | 4/20 | 0.51 |
| ▸ | EGFR | P00533 | 2/20 | 0.49 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.49 |
| ▸ | AURKA | O14965 | 1/20 | 0.49 |
| ▸ | SRC | P12931 | 1/20 | 0.49 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.49 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.49 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.49 |
| ▸ | AURKC | Q9UQB9 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | RET | P07949 | 2/20 | 0.42 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | CCR4 | P51679 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9132873 | 0.84 | MAPK1 (0.51) | MAPK14TTBK1TTBK2EGFRSRC | |
| SCHEMBL27463226 | 0.82 | MEN1 (0.59) | MAPK14TTBK1TTBK2EGFRMAPK1 | |
| SCHEMBL4245668 | 0.81 | MAPK14 (0.57) | MAPK14EGFRAURKAMAPK1RET | |
| SCHEMBL1116427 | 0.79 | SYK (0.67) | AURKA | |
| SCHEMBL2976781 | 0.78 | DHPS (0.48) | EGFRMAPK1RETPDGFRBKDR | |
| SCHEMBL858905 | 0.78 | MAPK14 (0.60) | MAPK14ERBB2AURKAPTK6MAPK1 | |
| SCHEMBL21257478 | 0.78 | RAPGEF4 (0.46) | MAPK14EGFRMAPK1RETPDGFRB | |
| SCHEMBL858313 | 0.78 | TTBK1 (0.63) | TTBK1TTBK2BRAFEGFRERBB2 | |
| SCHEMBL9133306 | 0.76 | MAPK1 (0.53) | MAPK14EGFRMAPK1CYP3A4RET | |
| SCHEMBL1920770 | 0.75 | CYP3A4 (0.72) | BRAFEGFRERBB2AURKASRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2029543-B1 | SUBSTITUTED 3-CYANOPYRIDINES AS PROTEIN KINASE INHIBITORS | WYETH LLC (US) | 2015-11-18 | — | — | EP | disclosed |
| US-7781591-B2 | Substituted 3-cyanopyridines as protein kinase inhibitors | WYETH LLC (US) | 2010-08-24 | — | — | US | disclosed |
| US-20070287708-A1 | Substituted 3-cyanopyridines as protein kinase inhibitors | WYETH LLC | 2007-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287708-A1 | Substituted 3-cyanopyridines as protein kinase inhibitors | CNKSR1, MAP3K1, MAP3K7 | MAPK14 227/4885TTBK1 223/4885TTBK2 362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.